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possible itching’) numeric rating scale, recorded daily during the first 2 weeks of
treatment and at clinic visits. Mediation modeling was used to determine the re-
lationship between ISS, the Physician’s Global Assessment (PGA, a clinicalmeasure
of psoriasis severity assessing erythema, induration, and scaling), and treatments
(2, 5, 15 mg BID vs placebo). Mediation modeling included ISS as the dependent
variable (averaged post-treatment ISS during weeks 2-12 for every patient), PGA as
the mediator variable (averaged post-treatment PGA score during weeks 2-12 for
every patient), and treatments (with each drug dose comparedwith placebo) as the
independent variables. Psychometric (correlational) analyses were performed on
ISS using post-baseline assessments. RESULTS: The direct effects of all CP-690,550
doses on ISS were 70%-81% (vs placebo; p0.001), indicating that drug effects on
pruritus were mostly independent of improvements in erythema, induration, and
scaling. Daily ISS measurements had acceptable test-retest reliability (intraclass
correlation: 0.83) in patients who did not change on PGA during the first 2 weeks of
the trial. Pearson correlations between ISS and other measures were consistent
with expectations; for example, weekly ISS correlated with weekly PGA (range:
0.30.5) and Patient Global Assessment (range: 0.60.7). CONCLUSIONS: In pa-
tients with psoriasis, CP-690,550 has a direct, beneficial effect on patient-reported
pruritus that is independent from improvements in clinician-reported psoriasis
severity. Post-baseline assessments of ISS showed favorable psychometric charac-
teristics, indicating its potential use as a simple tool for assessment of pruritus in
clinical trials.
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GAP ANALYSIS FOR PATIENT-REPORTED OUTCOMES MEASURES FOR ALOPECIA
Dennee-Sommers B1, Galipeau N1, Fitzgerald K1, Evans C1, Daniels S2, Burgess SM2
1MAPI Values, Boston, MA, USA, 2Allergan, Inc., Irvine, CA, USA
OBJECTIVES: To identify an existing patient-reported outcome (PRO) measure to
substantiate labeling or promotional claims for treatment in alopecia.METHODS:
MEDLINE®, PRO and Quality of Life Instruments (PROQOLID) and PRO and Drug
Marketing Authorizations (PROLabels) databases were searched and relevant in-
struments were identified by reviewing abstracts, articles, and labels for concepts
of interest (i.e., color/darkness, length, fullness/thickness, general appearance/
attractiveness, self-esteem). The initial instruments were further reviewed and
subsequently excluded if they were: not PROs (e.g., hair coverage), not specific to
scalp hair growth, or developed without patient input. The final list of instruments
was evaluated based on requirements outlined in the US Food and Drug Adminis-
tration’s Final PRO Guidance for Industry (e.g., development and confirmation of
conceptual framework, patient involvement in item generation, content validity,
recall period, response options, consideration of patient population used for devel-
opment in relation to future clinical trials). RESULTS: Forty-five instruments were
identified; 23were patient-reported, 17were investigator-rated, threewere devices
and two were objective hair measures. Forty-one were excluded based on the cri-
teria outlined. The four instruments considered further included alopecia-specific
items and instruments used to support the approval of drugs to stimulate hair
growth (e.g., Propecia®), specifically, the Kingsley Alopecia Questionnaire (KAP),
the Hair Growth Questionnaire, the Hair Problem List, and the Women’s Andro-
genic Alopecia Quality of Life Questionnaire (WAA-QOL). CONCLUSIONS: None of
the instruments met the PRO Guidance requirements; however, some could be
adapted. The Hair Growth Questionnaire could be revised and tested to confirm if
the content of the instrument is relevant for women with alopecia as it was devel-
oped based on male input only. Alternatively, the Hair Problem List or the WAA-
QOL could be supplemented to include more concepts of interest and tested to
confirm if the content of the instrument is relevant for both men and women with
alopecia.
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SYSTEMATIC REVIEW OF THE QUALITY OF LIFE LITERATURE IN CHILDREN
WITH ATOPIC DERMATITIS
Iskedjian M1, Navarro V2, Khondoker F1, Farah B3
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OBJECTIVES: A systematic review of the literature was performed to elicit the
published evidence relating to quality of life (QOL) in children with atopic derma-
titis (AD).METHODS:OVIDMEDLINE® and EMBASE™were explored by two review-
ers for a combined search with terms related to economics and QOL in a paediatric
population, for the period 1996-2010. This abstract reports the results of the QOL
review. Two reviewers browsed abstracts, retrieved suitable articles and summa-
rized key findings. A third person acted as overall reviewer and adjudicator in case
of disagreement. RESULTS: From an initial search yielding 704 references, 51 pri-
mary research articles were included in the review, 14 reporting on QOL as primary
outcome and 37 as secondary outcome. QOL as a primary outcomewas reported for
Europe (n7), North America (n4), Asia (n3), Australia (n1) and South America
(n1). One study reported preference-based outcomes. Most studieswere based on
AD-specific tools such as the Children’s Dermatology Life Quality Index or the
Dermatology Life Quality Index (n6), the Infants’ Dermatitis Quality of Life Index
(n4), theQuality of Life Index for Atopic Dermatitis or the Parent’s Index of Quality
of Life–Atopic Dermatitis (n2) and the Dermatitis Family Impact Questionnaire
(n5). One studywas based on general QOLmeasures from the 12-itemShort-Form
Health Survey (SF-12). The studies targeting very young children most often used
parents as proxies.Most studies pointed to an inverse correlation betweenQOL and
severity as well as correlation between various instruments. Studies reporting on
QOL as a secondary outcome confirmed those findings. CONCLUSIONS: There is a
clear lack of studies eliciting health state utilities. Furthermore, most AD-specific
tools do not provide a standard, quantitative measurement in relation to perfect
health as would do preference based studies required for cost-utility analyses.
Further research should focus on utility measurement.
Sensory Systems Disorders – Health Care Use & Policy Studies
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COMPARING HEALTH-RISK BURDEN AND TOTAL HEALTHCARE COSTS OF
PSORIASIS WITH TOP FIVE CHRONIC CONDITIONS
Naim A1, Pitts J2, Chen CY3, Wright D3, Chalk MB2, Edington D3
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OBJECTIVES: Psoriasis (PsO) is a chronic, episodic, immunological skin disease that
affects approximately 2-2.5% of US population. It may result in work productivity
loss and high overall healthcare costs for employers. However, the impact on
health-risks is not well studied. We compared health-risks, lost productivity, and
total direct healthcare costs among individuals with PsO and five most prevalent
chronic conditions. METHODS: Health-risk information and self-reported illness
days using health-risk assessment (HRA) data were examined and direct Health-
care costs (medical and pharmacy) using claims data for employees, retirees, and
their adult dependents of a large self-insured employer were compared from 2002-
2006 among individuals with RA and five most prevalent chronic conditions;
asthma, coronary artery disease/congestive heart failure (CAD/CHF), diabetes, hy-
pertension, chronic obstructive pulmonary disease (COPD). RESULTS: 54 individu-
als with PsOwere identified. The PsO cohort hadmoderate health-risk score (2.8/5)
which was comparable to individuals with asthma (2.8/5), CHF (2.9), hypertension
(2.6) and lower than diabetes (3.2/5) and COPD (3.4/5). A higher proportion (35.2%) of
individuals with PsO had 5 illness days per year as compared with individuals
with asthma (31.8%), CAD/CHF (25.9%), hypertension (20.4%), diabetes (28.4%), and
COPD (33%). Annual direct healthcare costs were also higher for individuals with
RA ($28,933) as compared to individuals with asthma ($25,814), CAD/CHF ($22,916),
hypertension ($18,632), and diabetes ($28,224), and lower as compared to individ-
uals with COPD ($38,839). CONCLUSIONS: Individuals with PsO have similar
health-risks but higher illness days, and direct healthcare costs as compared to the
individuals with five most prevalent chronic conditions. Psoriasis is a high costs
and lost productivity driver for employers. Population health based programs that
engage employees in appropriately managing their chronic conditions can help
employers reduce health-risks, improve productivity, andmay help reduce health-
care costs as well.
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MEDICATION CHOICE AND ASSOCIATED HEALTH CARE OUTCOMES AND
COSTS FOR PATIENTS WITH ACNE AND ACNE RELATED CONDITIONS IN THE
UNITED STATES
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OBJECTIVES: Acne is a common condition for which multiple treatment options
are available. The patterns of pharmacotherapy for acne and similar conditions,
and the effect of those patterns on cost, are not well characterized. This study
examined the impacts of patient demographics and medication choices on pa-
tient’s health status and associated medication costs. METHODS: A retrospective
cross-sectional study was conducted using the 2007 Medical Expenditure Panel
Survey (MEPS) database. Information onpatient demographics, health status,med-
ication utilization, and medication costs were obtained from the database repre-
senting 3,784,816 patients with acne and similar conditions. RESULTS: Weighted
multiple linear regression analyses indicated that the use of topical retinoids was
preferred in combination with other treatments rather than its monotherapy. Oral
antibiotics were widely prescribed and its use was associated with a significant
decrease in total annual prescription spending. Use of oral retinoids and oral con-
traceptives increased the annual prescription costs significantly. Increase in an-
nual drug refills was not associated with the improvement in health status.
CONCLUSIONS: We observed an association with medication choice for acne and
acne related conditions onmedication spending. Pharmacologic treatment of acne
significantly adds to acne related annual healthcare costs compared to non phar-
macologic treatment.
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EXPENDITURES IN MEDICAID-ENROLLED CHILD WITH ATOPIC DERMATITIS
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OBJECTIVES: To identify factors that predict adherence to topical medication in
pediatric population with atopic dermatitis (AD), and assess their impact on
healthcare expenditures. METHODS: AD patient’s age under 12 years old using
topic corticosteroid or topical calcineurin inhibitor (TCI) was identified using Mar-
ketScanTM Medicaid database from 2005 to 2007. Adherence to ADmedication and
costs for all healthcare claims and costs for AD related claims were outcomes of
interest and measured over 12 months when AD medication started. Medication
adherence was measured using medication possession ratio. Multiple regression
analysis was carried to examine predictors for medication adherence and their
predictions on healthcare costs. RESULTS: 4,182 patients were included, with a
mean age of 4 years. Adherence to ADmedication average was low (41%), with the
lowest rates in patients with low potency corticosteroid therapy alone including
alclometasone, desonide or hydrocortisone (39%) and the highest rates in those
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who used combination therapy (topical corticosteroid and TCI) (68%). Type of
health plan, Medicaid eligibility status, number of therapeutic class, comorbidity,
hospitalization or not andAD related costs during 12months before ADmedication
started were significantly associated with ADmedication adherence. Adherence to
AD medication was significantly negatively associated with total annual health-
care costs (p0.001) and with AD related costs (p0.001), adjusted for patient de-
mographic, comorbidity, and healthcare utilization characteristics before ADmedica-
tion started.CONCLUSIONS: Poor adherence to topical medication was observed in
pediatric AD, and adherence rates differed by the type and combination of AD
medication therapy. The detrimental effect of poor adherence on healthcare eco-
nomic outcome was significant, which implies a need to improve adherence in
order to reduce the financial impact of non-adherence. Factors which could con-
tribute non-adherence and financial burden need to be refined and targeted by
intervention to improve humanistic and economic outcomes of treatment.
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PATIENT’S EVALUATION OF THE QUICKNESS OF ACTION OF GINGIVAL
INFLAMMATION TREATMENTS
Mattout P1, Rahhali N2, Watt M3, Auges M2, Taieb C2
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OBJECTIVES: Gingivitis is defined as lesions on the gingival margin, expressed
through gum redness, bleeding, localized edema, and gingival sensitivity. It ismost
often caused by substances produced by bacterial plaque, or dental biofilm, which
develops along the gingival crevice.To evaluate, using patient’s interview results,
the quickness of action of several treatments for gingival inflammation.
METHODS:Observational, prospective, longitudinal,multicentric study carried out
in France, using data collected by participating dentists and dental surgeons.
RESULTS:A total of 316 patientswith gingivitis returned their questionnaire. wom-
en: 65.25%, current smokers:22.93% and 28.51% were ex-smokers. Light and heavy
bleeding during brushing was reported by 45.74% and 33.33% of patients respec-
tively. 45.70% reported visible redness, 56.34% reported swollen gums, 13.19% had
lesions, but above all 50.52% reported pain. Finally, 62.26% had previous history of
gingivitis symptoms. As for dental surgeons: 96.36% had performed scaling, 15.15%
gingival curettage, and 13.64% radicular resurfacing. A total of 78.4% judged gingi-
val inflammation to be moderate to severe, 63.10% said it had spread (30%). In
terms of treatment: 98.62% gave patients oral hygiene advice, 87.98% advised on
brushingmethods, 69.91% recommended specific toothpaste, and 78.85% amouth-
wash. A total of 30.61% had generalized inflammation after 1 month, reducing to
just 11.24% at 2months and 15.63% at 3months. A total of 88.08% reported improve-
ment in inflammation after the first month, 91.59% at 2 months and 93.59% at 3
months. A total of 83.93% felt less pain after 1 month of treatment, 87.90% after 2
months and 92.08% after 3 months.(p0.0418). 89.13% felt their treatment was effec-
tive after 1month, 97.79% after 2 months and 96.15% after 3 months.(p0.0036).
CONCLUSIONS: In terms of satisfaction, 86.52% were satisfied after 1 month, 94.85%
after 2months and 95.92% after 3months. (p0.0076). 87.57% felt their treatmentwas
easy to follow after 1month, 86.76% after 2months and 92.08% after 3months. Above
all, after the first month of treatment, 88.83% said they would continue using the
treatment in prevention even after complete disappearance of gingivitis.
Sensory Systems Disorders – Research on Methods
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EFFECT OF TREATMENT SWITCH ON THE COST-EFFECTIVENESS OF BIOLOGICS
IN PSORIASIS IN PERU AND COLOMBIA
Alandete JC
Janssen-Cilag, Bogota, Colombia
OBJECTIVES: To evaluate the effect of treatment switch on the cost-effectiveness
of biologics used in patients with moderate or severe psoriasis in Colombia and
Perú. METHODS: In a previous study (Alandete, JC accepted in the ISPOR 13th
Anual European Congress) cost effectiveness of etanercept, adalimumab,
ustekinumab and infliximab was estimated based on label information for first-
(induction) year and second(maintenance) year assuming a 100% treatment
continuation ($1USDCOL$1.832SOL$2.75). For etanercept two induction
schemes were considered: 50mg weekly 52 weeks-D1- and 100mg 12 weeks fol-
lowed by 50 mg 40 weeks-D2-. Effectiveness was evaluated as 75% reduction in
Psoriasis Area and Severity Index-PASI 75- infliximab80%; ustekinumab69%;
adalimumab59%; etanerceptD2-52%; etanerceptD139%. Infliximab and
ustekinumab effectiveness were not significantly different. Both were significantly
superior to etanercept (Hawkins et al. meta-analysis presented in the 14th Interna-
tional ISPOR). In this abstract we developed a new model estimating switching
probabilities due to treatment failure atweek 12 and adverse events. Biologics costs
were adjusted considering time on the pre and post-switching periods. Treatment
effectiveness was adjusted when biologics were used after switching due to treat-
ment failure. RESULTS: Introduction of switching effect ratified ustekinumab dom-
inance in Colombia ($US44,675 in 2 years) generating cost savings of -$US4.049
versus etanerceptD1; -$US4.049 versus adalimumab; -$US7.844 versus etaner-
ceptD2 and -$US27.517 versus infliximab; with higher or same effectiveness than
the other biologics in that country. In Peru, ustekinumab changed from being the
most cost-effective option and became the dominant option ($US41.827 in 2 years)
generating cost savings of -$US283 versus etanerceptD1; -$US489 versus adali-
mumab; -$US3581 versus etanerceptD2 and -$US13.499 versus infliximab.
CONCLUSIONS: In the studied countries inclusion of the switching effect due to
treatment failure and adverse events ratifies cost-savings observed in Colombia
and makes ustekinumab the cost-saving option in Peru. These results corroborate
those observed in the USA and Europe.
PSS28
EFFECT OF DIFFERENT RECALL PERIODS ON DRY EYE SYMPTOM RATINGS
Ruiz WM1, Li JZ2, Johnson ME3
1G&S Research, Inc., Indianapolis, IN, USA, 2Pfizer, Inc., San Diego, CA, USA, 3Bristol Eye
Hospital, Bristol, UK
OBJECTIVES: Clinical studies of dry eye disease (DED), a highly symptomatic dis-
ease, often ask patients to evaluate their DED symptoms using patient-reported
outcomes instruments. Most of these instruments use a one-week recall period.
The effect of this recall period on the accuracy of DED symptom assessments has
not been documented. The purpose of our research was to compare self-reported
DED symptoms between one-week and daily recall periods. METHODS: We en-
rolled 156 DED patients to a web-based observational study to assess their DED
symptoms once a day for 9 days. For each of the 14 symptoms, we asked the
patients to rate the frequency and intensity on a 0-6 rating scale, with a higher
score indicatingworse symptom. The assessments onDays 1 and 9 had a one-week
recall period, while the assessments on Days 2-8 had a one-day recall period. We
then calculated the mean weekly scores for Day 1 and Day 9 and the mean daily
scores for Days 2-8, and tested the differences between themean weekly and daily
scores using matched-pair t tests without multiplicity adjustment. RESULTS: The
Day 1mean weekly scores were significantly higher than themean daily scores for
all 14 symptoms in both frequency and intensity. The Day 1 mean weekly scores
were also significantly higher than the Day 9 mean weekly scores in 10 frequency
and 11 intensity scores. The Day 9 mean weekly scores were slightly higher than
the daily scores; however, most of the differences were not statistically significant.
CONCLUSIONS: Patients’ self-ratings of their DED symptoms using a one-week
recall period are consistently inflated when compared to their ratings using a one-
day recall period. Such inflation should be considered when designing clinical
studies for DED.
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DEVELOPMENT OF THE MODIFIED OCULAR COMFORT INDEX (MOCI)
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OBJECTIVES: Dry eye disease (DED) is characterized by symptoms of ocular dis-
comfort, visual disturbance and reduced tolerance to environmental stressors.
DED has a significant negative impact on the quality of life (QOL) of persons af-
fected, and imposes a massive burden on medical resources owing to its high
prevalence and chronic nature. It is not known if available patient-reported out-
come (PRO) instruments fully capture the scope of DED symptoms and their impact
on QOL. The purpose of our ongoing research is to develop a PRO instrument that
meets the needs of clinical studies investigating potential treatments for DED.
METHODS: Patients with DED in five countries (United States, United Kingdom,
Spain, Japan and Korea) were interviewed to identify their symptoms and the im-
pact of the disease on QOL (n120). Based on these results, itemswere drafted that
were tested in two web-based studies with mild-moderate DED subjects (n106
and 156) and face-to-face interviews with severe DED subjects (n22). RESULTS:
Items enquiring about 8 additional symptom experiences (16 items grouped in
doublets asking about frequency/intensity) were added to the original Ocular Com-
fort Index (OCI) using the same question format and response structure (fluctuat-
ing vision, light sensitivity, redness, foreign body sensation, excessive tearing, ex-
cessive blinking, ocular irritation and stickiness). Additionally, 2 items that
enquired about the most bothersome symptom and the extent of bother, and 12
items that appraised how symptoms interfered with the ability to perform daily
activities were included. CONCLUSIONS: Patient interviews suggest that available
PRO instruments do not fully capture the scope of DED symptoms and their impact
on QOL. The modified OCI (mOCI) will be used in clinical studies to facilitate its
refinement and validation.
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BURDEN OF INFANTILE HEMANGIOMA: DEVELOPMENT OF A QUESTIONNAIRE
Taieb C1, Voisard JJ2, Ruiz F3
1PFSA, Boulogne Billancourt, France, 2PFD, Lavaur, France, 3Clinsearch, Bagneux, France
OBJECTIVES: Infantile hemangioma (IH) develops during the first weeks of life; it
normally forms within 3to6 months, then regresses very slowly over a duration of
3 to 7 years. In complicated forms, it is possible to encounter haemorrhaging,
necroses and ulcerations, infections and, more exceptionally, respiratory distress,
cardiovascular shunt. To explore the handicap, in its largest sense, generated by IH
using a questionnaire to express the burden on the daily life of the parents.
METHODS: The questionnaire was developed following a strict methodological
process, involving amultidisciplinary team incorporating various players (doctors,
nurses, social workers) who are involved in the treatment of patients or who are
specialised in the construction of questionnaires. A review of the literature and
discussions with the families were conducted in order to identify the concepts
related to the pathology. RESULTS: Exploratory assessments showed that the con-
cept of burden could be structured around two main modules: assess the impact
directly for the first-module. The consequences of HI on daily life, family and
personal relationships, work, financial situation and psychological impact for the
second-module. A third module focuses on the behaviour of the child; this module
will evolve over time and depending on the analyses. Fifty-six preliminary items
were identified following a first discussion. A first analysis managed to reduce
these items to 36 whilst conserving the 3 modules but making it easier to use the
analysis. CONCLUSIONS: The Hemangioma-Burden-Questionnaire will allow cli-
nicians to better understand the impact and consequences of the pathology on the
family. It will also allow the development of the burden to be monitored according
to the rate of development of the illness and its treatment.It will also allow the
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